Metabesity 2022: Preempting Age-Related Chronic Diseases and Disabilities

How Do We Get There, Sooner Than Later

A wide spectrum of approved drugs and marketed nutritional products are proposed for targeting the biologic hallmarks of aging.

The aim is to show a product’s safety and effectiveness for preempting multiple age-related chronic diseases and disability—and to do so sooner than later.

The proposed session will examine major examples of assets ranging from nutrients to novel, unapproved pharmacologic agents, with repurposed approved drugs and their combinations in between.

Moderator:
Jay Skyler, MD, Professor of Medicine, Pediatrics, & Psychology, in the Division of Endocrinology Diabetes & Metabolism, Department of Medicine, University of Miami Leonard M. Miller School of Medicine

Discussants:
Nir Barzilai, MD, Professor, Department of Medicine (Endocrinology), Professor, Department of Genetics, Ingeborg and Ira Leon Rennert Chair in Aging Research, Director, Institute for Aging Research

Joe Baur, PhD, Professor of Physiology, Perelman School of Medicine, University of Pennsylvania

Alexander Fleming, MD, Founder and President of The Kitalys Institute

Steven Gough, MD, FRCP, Senior Vice President, Global CMO, Novo Nordisk

Catherine Kwik-Uribe, PhD, VP, Scientific and Regulatory Affairs, Applied Science and Nutrition, Mars Edge

Hans-Juergen Woerle, MD, PhD, Chief Scientific and Medical Officer, Nestle HealthScience

Joan Mannick, MD, PhD, Chief Executive Officer of Tornado Therapeutics

Michael Zemel, PhD, Chief Scientific Officer, Kinexum